Brugelion的个人主页 - 老虎社区

Brugelion

Brugelion

暂无个人介绍

IP属地：未知

184关注

17粉丝

0主题

0勋章

2021-11-08

Huat ar! Buy the dip

Tesla shares fell more than 7% in premarket trading.

2021-11-01

Huat ar!

Novavax stock surged 14.2% in premarket trading

2021-11-05

Huat ar

Pfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%

2021-10-28

Huat ar! Buy the dip!

Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint

2021-04-30

这只怎么样？

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3582276661346153,"uuid":"3582276661346153","gmtCreate":1619182730345,"gmtModify":1619755310896,"name":"Brugelion","pinyin":"brugelion","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":17,"headSize":184,"tweetSize":101,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.10","exceedPercentage":"60.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.59%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":845467997,"gmtCreate":1636362260546,"gmtModify":1636362260842,"author":{"id":"3582276661346153","authorId":"3582276661346153","name":"Brugelion","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Huat ar! Buy the dip","listText":"Huat ar! Buy the dip","text":"Huat ar! Buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845467997","repostId":"1114414245","repostType":2,"repost":{"id":"1114414245","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636362022,"share":"https://www.laohu8.com/m/news/1114414245?lang=&edition=full","pubTime":"2021-11-08 17:00","market":"us","language":"en","title":"Tesla shares fell more than 7% in premarket trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1114414245","media":"Tiger Newspress","summary":"Musk, the world's richest person, tweeted on Saturday that he would offload 10% of his stock if users of the social media network approved the proposal.The Twitter poll asking Musk's followers if he should sell stock garnered more than 3.5 million votes, and 57.9% of people voted \"Yes\".","content":"<p>Tesla shares&nbsp;fell&nbsp;more&nbsp;than&nbsp;7%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/e3820ad4455a65386786b07a82e72c6e\" tg-width=\"896\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p>\n<p>Musk, the world's richest person, tweeted on Saturday that he would offload 10% of his stock if users of the social media network approved the proposal.</p>\n<p>The Twitter poll asking Musk's followers if he should sell stock garnered more than 3.5 million votes, and 57.9% of people voted \"Yes\".</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla shares fell more than 7% in premarket trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla shares fell more than 7% in premarket trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-08 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla shares&nbsp;fell&nbsp;more&nbsp;than&nbsp;7%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/e3820ad4455a65386786b07a82e72c6e\" tg-width=\"896\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p>\n<p>Musk, the world's richest person, tweeted on Saturday that he would offload 10% of his stock if users of the social media network approved the proposal.</p>\n<p>The Twitter poll asking Musk's followers if he should sell stock garnered more than 3.5 million votes, and 57.9% of people voted \"Yes\".</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114414245","content_text":"Tesla shares fell more than 7% in premarket trading.\n\nMusk, the world's richest person, tweeted on Saturday that he would offload 10% of his stock if users of the social media network approved the proposal.\nThe Twitter poll asking Musk's followers if he should sell stock garnered more than 3.5 million votes, and 57.9% of people voted \"Yes\".","news_type":1},"isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846763684,"gmtCreate":1636114887045,"gmtModify":1636114887418,"author":{"id":"3582276661346153","authorId":"3582276661346153","name":"Brugelion","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Huat ar","listText":"Huat ar","text":"Huat ar","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846763684","repostId":"1166866310","repostType":4,"repost":{"id":"1166866310","pubTimestamp":1636112660,"share":"https://www.laohu8.com/m/news/1166866310?lang=&edition=full","pubTime":"2021-11-05 19:44","market":"us","language":"en","title":"Pfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166866310","media":"Bloomberg","summary":"Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awa","content":"<ul>\n <li>Drug reduced Covid hospitalizations by 89% in clinical trial</li>\n <li>Pfizer shares surge 11%; Merck pill awaiting U.S. approval</li>\n</ul>\n<p>Pfizer Inc.&nbsp;said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%, a result that has the potential to upend how the disease caused by the coronavirus is treated and alter the course of the pandemic. The shares surged 11%.</p>\n<p>The drugmaker said in a statement on Friday that it was no longer taking new patients in a clinical trial of the treatment “due to the overwhelming efficacy” and planned to submit the findings to U.S. regulatory authorities for emergency authorization as soon as possible.</p>\n<p>The results mean there are now two promising candidates for treating Covid-19 patients early in the course of the disease. Last month,Merck &amp; Co.&nbsp;and partner Ridgeback Biotherapeutics LP submitted their experimental pill to regulators after a study showed it slashed the risk of getting seriously ill or dying&nbsp;by half&nbsp;in patients with mild-to-moderate Covid-19.</p>\n<p>Pfizer gained 11% in premarket U.S. trading, while Merck fell 6.6%. Some vaccine makers lost ground, with&nbsp;Moderna Inc&nbsp;.down 4.5% and Pfizer partner&nbsp;BioNTech&nbsp;SE slipping 4% in German trading.</p>\n<p>A pill that could be taken at home at the first sign of symptoms is a crucial tool for taming the Covid-19 crisis globally, so long as it’s widely available. A Pfizer spokesperson said submissions to other regulatory agencies will occur shortly after the U.S. filing.</p>\n<p>In Pfizer’s trial of 1,219 unvaccinated adults, five days of treatment with its drug dramatically reduced the rate of hospitalization when it was started within either three days or five days of symptom onset, the company said. The drug, Paxlovid, binds to an enzyme called a protease to stop the virus from replicating itself. Some drugs for HIV work in a similar way.</p>\n<p>Overall, just 0.8% of people who started treatment within three days of getting sick ended up in the hospital and no one died, while 7% of people who got a placebo in that window were later hospitalized or died. Similar results were found when the drug was started within five days of symptom onset. The result, which hasn’t been published in a medical journal, was highly statistically significant, Pfizer said.</p>\n<p><b>Acute Need</b></p>\n<p>Current treatment options for Covid aren’t ideal. Monoclonal antibodies from companies like&nbsp;Regeneron Pharmaceuticals Inc.&nbsp;and&nbsp;Eli Lilly &amp; Co.&nbsp;reduce hospitalizations, but the infusions are hard to manufacture and must be given in a medical office, adding to the strain on health systems.</p>\n<p>Other medications like&nbsp;Gilead Sciences Inc.’s remdesivir are used to treat much sicker people who are already in the hospital. Low-cost steroid dexamethasone, while very effective, is usually only given to gravely ill patients.</p>\n<p>The need for a pill is so acute that Merck has&nbsp;already agreed&nbsp;to allow generic drugmakers to apply for licenses to make its treatment for more than 100 low- and middle-income nations, before it has even been cleared in the U.S. The U.K.’s drug regulators became the first in the world&nbsp;to greenlight&nbsp;Merck’s drug Thursday after a swift review.</p>\n<p>Now Pfizer’s pill, which works by a different mechanism, appears to have produced even better results in high-risk patients. The trial was stopped early by independent monitors because the effect was so impressive.</p>\n<p>“We are really over the moon that we did see such high efficacy in this study. It has tremendous implications for patients globally,” said Annaliesa Anderson, chief scientific officer for Pfizer’s hospitals business unit, which includes its antiviral work.</p>\n<p>In addition to the current trial in high-risk patients, Pfizer is also testing the drug in standard-risk patients, a study that included some vaccinated people who had breakthrough infections.</p>\n<p>In a third large trial, Pfizer is exploring if the drug could be used as a prophylactic medicine for people who live with someone who has come down with Covid-19, meaning a person would take the drug to avoid contracting the virus.</p>\n<p><b>Old Molecule</b></p>\n<p>The pill was internally developed by Pfizer researchers in the U.S. and U.K. During the early pandemic shutdowns, the scientists agreed to come back to their labs in an urgent effort to develop anti-Covid pills, Anderson said. Company researchers “worked around the clock to design this molecule” in a highly-compressed timeframe, she said.</p>\n<p>They dusted off an old experimental antiviral drug that Pfizer had developed after the original SARS epidemic, a coronavirus cousin to Covid-19 that killed about 800 people starting in late 2002. The old drug needed to be administered intravenously. But by July of last year, the Pfizer researchers tweaked the original molecule and came up with a new compound that turned out to be highly potent against Covid-19 and other coronaviruses in the test tube -- and could be used as a pill.</p>\n<p>The Pfizer drug works to block a crucial enzyme that the Covid-19 virus needs to replicate. It is taken twice a day for five days and used in combination with a second medicine called ritonavir that helps the Pfizer compound stay in the bloodstream longer.</p>\n<p>Pfizer said it planned to offer the antiviral therapy through a tiered pricing approach during the pandemic. High and upper-middle income countries will pay more than lower income countries, it said. The drugmaker didn’t say exactly how much it would charge.</p>\n<p>A Pfizer spokesperson said the company currently expects to produce more than 180,000 packs of the drug by the end of this year, and anticipates making at least 50 million packs by the end of 2022, with 21 million produced in the first half of the year.</p>\n<p></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awaiting U.S. approval\n\nPfizer Inc. said its Covid-19 pill reduced hospitalizations and deaths in high-...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166866310","content_text":"Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awaiting U.S. approval\n\nPfizer Inc. said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%, a result that has the potential to upend how the disease caused by the coronavirus is treated and alter the course of the pandemic. The shares surged 11%.\nThe drugmaker said in a statement on Friday that it was no longer taking new patients in a clinical trial of the treatment “due to the overwhelming efficacy” and planned to submit the findings to U.S. regulatory authorities for emergency authorization as soon as possible.\nThe results mean there are now two promising candidates for treating Covid-19 patients early in the course of the disease. Last month,Merck & Co. and partner Ridgeback Biotherapeutics LP submitted their experimental pill to regulators after a study showed it slashed the risk of getting seriously ill or dying by half in patients with mild-to-moderate Covid-19.\nPfizer gained 11% in premarket U.S. trading, while Merck fell 6.6%. Some vaccine makers lost ground, with Moderna Inc .down 4.5% and Pfizer partner BioNTech SE slipping 4% in German trading.\nA pill that could be taken at home at the first sign of symptoms is a crucial tool for taming the Covid-19 crisis globally, so long as it’s widely available. A Pfizer spokesperson said submissions to other regulatory agencies will occur shortly after the U.S. filing.\nIn Pfizer’s trial of 1,219 unvaccinated adults, five days of treatment with its drug dramatically reduced the rate of hospitalization when it was started within either three days or five days of symptom onset, the company said. The drug, Paxlovid, binds to an enzyme called a protease to stop the virus from replicating itself. Some drugs for HIV work in a similar way.\nOverall, just 0.8% of people who started treatment within three days of getting sick ended up in the hospital and no one died, while 7% of people who got a placebo in that window were later hospitalized or died. Similar results were found when the drug was started within five days of symptom onset. The result, which hasn’t been published in a medical journal, was highly statistically significant, Pfizer said.\nAcute Need\nCurrent treatment options for Covid aren’t ideal. Monoclonal antibodies from companies like Regeneron Pharmaceuticals Inc. and Eli Lilly & Co. reduce hospitalizations, but the infusions are hard to manufacture and must be given in a medical office, adding to the strain on health systems.\nOther medications like Gilead Sciences Inc.’s remdesivir are used to treat much sicker people who are already in the hospital. Low-cost steroid dexamethasone, while very effective, is usually only given to gravely ill patients.\nThe need for a pill is so acute that Merck has already agreed to allow generic drugmakers to apply for licenses to make its treatment for more than 100 low- and middle-income nations, before it has even been cleared in the U.S. The U.K.’s drug regulators became the first in the world to greenlight Merck’s drug Thursday after a swift review.\nNow Pfizer’s pill, which works by a different mechanism, appears to have produced even better results in high-risk patients. The trial was stopped early by independent monitors because the effect was so impressive.\n“We are really over the moon that we did see such high efficacy in this study. It has tremendous implications for patients globally,” said Annaliesa Anderson, chief scientific officer for Pfizer’s hospitals business unit, which includes its antiviral work.\nIn addition to the current trial in high-risk patients, Pfizer is also testing the drug in standard-risk patients, a study that included some vaccinated people who had breakthrough infections.\nIn a third large trial, Pfizer is exploring if the drug could be used as a prophylactic medicine for people who live with someone who has come down with Covid-19, meaning a person would take the drug to avoid contracting the virus.\nOld Molecule\nThe pill was internally developed by Pfizer researchers in the U.S. and U.K. During the early pandemic shutdowns, the scientists agreed to come back to their labs in an urgent effort to develop anti-Covid pills, Anderson said. Company researchers “worked around the clock to design this molecule” in a highly-compressed timeframe, she said.\nThey dusted off an old experimental antiviral drug that Pfizer had developed after the original SARS epidemic, a coronavirus cousin to Covid-19 that killed about 800 people starting in late 2002. The old drug needed to be administered intravenously. But by July of last year, the Pfizer researchers tweaked the original molecule and came up with a new compound that turned out to be highly potent against Covid-19 and other coronaviruses in the test tube -- and could be used as a pill.\nThe Pfizer drug works to block a crucial enzyme that the Covid-19 virus needs to replicate. It is taken twice a day for five days and used in combination with a second medicine called ritonavir that helps the Pfizer compound stay in the bloodstream longer.\nPfizer said it planned to offer the antiviral therapy through a tiered pricing approach during the pandemic. High and upper-middle income countries will pay more than lower income countries, it said. The drugmaker didn’t say exactly how much it would charge.\nA Pfizer spokesperson said the company currently expects to produce more than 180,000 packs of the drug by the end of this year, and anticipates making at least 50 million packs by the end of 2022, with 21 million produced in the first half of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849597082,"gmtCreate":1635764681181,"gmtModify":1635764681328,"author":{"id":"3582276661346153","authorId":"3582276661346153","name":"Brugelion","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Huat ar!","listText":"Huat ar!","text":"Huat ar!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/849597082","repostId":"1118499473","repostType":2,"repost":{"id":"1118499473","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635764611,"share":"https://www.laohu8.com/m/news/1118499473?lang=&edition=full","pubTime":"2021-11-01 19:03","market":"us","language":"en","title":"Novavax stock surged 14.2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1118499473","media":"Tiger Newspress","summary":"Biotechnology company Novavax stock surged 14.2% in premarket trading after filing for authorization","content":"<p>Biotechnology company Novavax stock surged 14.2% in premarket trading&nbsp;after filing for authorization of its COVID-19 vaccine in multiple countries and regions.</p>\n<p><img src=\"https://static.tigerbbs.com/1f507bc8048dfc7207968fa1251226ef\" tg-width=\"849\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax,&nbsp;Inc.&nbsp;today announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine inCanada. In addition, the company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.</p>\n<p>In addition,Novavax&nbsp;have&nbsp;announced the completion of its rolling regulatory submission to the U.K.;</p>\n<p>Novavax has announced that it has already completed its rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its COVID-19 vaccine candidate.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax stock surged 14.2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax stock surged 14.2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-01 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biotechnology company Novavax stock surged 14.2% in premarket trading&nbsp;after filing for authorization of its COVID-19 vaccine in multiple countries and regions.</p>\n<p><img src=\"https://static.tigerbbs.com/1f507bc8048dfc7207968fa1251226ef\" tg-width=\"849\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax,&nbsp;Inc.&nbsp;today announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine inCanada. In addition, the company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.</p>\n<p>In addition,Novavax&nbsp;have&nbsp;announced the completion of its rolling regulatory submission to the U.K.;</p>\n<p>Novavax has announced that it has already completed its rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its COVID-19 vaccine candidate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118499473","content_text":"Biotechnology company Novavax stock surged 14.2% in premarket trading after filing for authorization of its COVID-19 vaccine in multiple countries and regions.\n\nNovavax, Inc. today announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine inCanada. In addition, the company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.\nIn addition,Novavax have announced the completion of its rolling regulatory submission to the U.K.;\nNovavax has announced that it has already completed its rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its COVID-19 vaccine candidate.","news_type":1},"isVote":1,"tweetType":1,"viewCount":716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854187814,"gmtCreate":1635428404119,"gmtModify":1635428506378,"author":{"id":"3582276661346153","authorId":"3582276661346153","name":"Brugelion","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Huat ar! Buy the dip!","listText":"Huat ar! Buy the dip!","text":"Huat ar! Buy the dip!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854187814","repostId":"1153909226","repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"tweetType":1,"viewCount":570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":103118324,"gmtCreate":1619755138468,"gmtModify":1634210147039,"author":{"id":"3582276661346153","authorId":"3582276661346153","name":"Brugelion","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"这只怎么样？","listText":"这只怎么样？","text":"这只怎么样？","images":[{"img":"https://static.tigerbbs.com/59a8ba9379974aa2c5a043819af37e6a","width":"1125","height":"2197"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/103118324","isVote":1,"tweetType":1,"viewCount":525,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"hots":[{"id":845467997,"gmtCreate":1636362260546,"gmtModify":1636362260842,"author":{"id":"3582276661346153","authorId":"3582276661346153","name":"Brugelion","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Huat ar! Buy the dip","listText":"Huat ar! Buy the dip","text":"Huat ar! Buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845467997","repostId":"1114414245","repostType":2,"repost":{"id":"1114414245","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636362022,"share":"https://www.laohu8.com/m/news/1114414245?lang=&edition=full","pubTime":"2021-11-08 17:00","market":"us","language":"en","title":"Tesla shares fell more than 7% in premarket trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1114414245","media":"Tiger Newspress","summary":"Musk, the world's richest person, tweeted on Saturday that he would offload 10% of his stock if users of the social media network approved the proposal.The Twitter poll asking Musk's followers if he should sell stock garnered more than 3.5 million votes, and 57.9% of people voted \"Yes\".","content":"<p>Tesla shares&nbsp;fell&nbsp;more&nbsp;than&nbsp;7%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/e3820ad4455a65386786b07a82e72c6e\" tg-width=\"896\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p>\n<p>Musk, the world's richest person, tweeted on Saturday that he would offload 10% of his stock if users of the social media network approved the proposal.</p>\n<p>The Twitter poll asking Musk's followers if he should sell stock garnered more than 3.5 million votes, and 57.9% of people voted \"Yes\".</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla shares fell more than 7% in premarket trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla shares fell more than 7% in premarket trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-08 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla shares&nbsp;fell&nbsp;more&nbsp;than&nbsp;7%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/e3820ad4455a65386786b07a82e72c6e\" tg-width=\"896\" tg-height=\"614\" width=\"100%\" height=\"auto\"></p>\n<p>Musk, the world's richest person, tweeted on Saturday that he would offload 10% of his stock if users of the social media network approved the proposal.</p>\n<p>The Twitter poll asking Musk's followers if he should sell stock garnered more than 3.5 million votes, and 57.9% of people voted \"Yes\".</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114414245","content_text":"Tesla shares fell more than 7% in premarket trading.\n\nMusk, the world's richest person, tweeted on Saturday that he would offload 10% of his stock if users of the social media network approved the proposal.\nThe Twitter poll asking Musk's followers if he should sell stock garnered more than 3.5 million votes, and 57.9% of people voted \"Yes\".","news_type":1},"isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849597082,"gmtCreate":1635764681181,"gmtModify":1635764681328,"author":{"id":"3582276661346153","authorId":"3582276661346153","name":"Brugelion","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Huat ar!","listText":"Huat ar!","text":"Huat ar!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/849597082","repostId":"1118499473","repostType":2,"repost":{"id":"1118499473","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635764611,"share":"https://www.laohu8.com/m/news/1118499473?lang=&edition=full","pubTime":"2021-11-01 19:03","market":"us","language":"en","title":"Novavax stock surged 14.2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1118499473","media":"Tiger Newspress","summary":"Biotechnology company Novavax stock surged 14.2% in premarket trading after filing for authorization","content":"<p>Biotechnology company Novavax stock surged 14.2% in premarket trading&nbsp;after filing for authorization of its COVID-19 vaccine in multiple countries and regions.</p>\n<p><img src=\"https://static.tigerbbs.com/1f507bc8048dfc7207968fa1251226ef\" tg-width=\"849\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax,&nbsp;Inc.&nbsp;today announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine inCanada. In addition, the company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.</p>\n<p>In addition,Novavax&nbsp;have&nbsp;announced the completion of its rolling regulatory submission to the U.K.;</p>\n<p>Novavax has announced that it has already completed its rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its COVID-19 vaccine candidate.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax stock surged 14.2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax stock surged 14.2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-01 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biotechnology company Novavax stock surged 14.2% in premarket trading&nbsp;after filing for authorization of its COVID-19 vaccine in multiple countries and regions.</p>\n<p><img src=\"https://static.tigerbbs.com/1f507bc8048dfc7207968fa1251226ef\" tg-width=\"849\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p>\n<p>Novavax,&nbsp;Inc.&nbsp;today announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine inCanada. In addition, the company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.</p>\n<p>In addition,Novavax&nbsp;have&nbsp;announced the completion of its rolling regulatory submission to the U.K.;</p>\n<p>Novavax has announced that it has already completed its rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its COVID-19 vaccine candidate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118499473","content_text":"Biotechnology company Novavax stock surged 14.2% in premarket trading after filing for authorization of its COVID-19 vaccine in multiple countries and regions.\n\nNovavax, Inc. today announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine inCanada. In addition, the company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.\nIn addition,Novavax have announced the completion of its rolling regulatory submission to the U.K.;\nNovavax has announced that it has already completed its rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its COVID-19 vaccine candidate.","news_type":1},"isVote":1,"tweetType":1,"viewCount":716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846763684,"gmtCreate":1636114887045,"gmtModify":1636114887418,"author":{"id":"3582276661346153","authorId":"3582276661346153","name":"Brugelion","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Huat ar","listText":"Huat ar","text":"Huat ar","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846763684","repostId":"1166866310","repostType":4,"repost":{"id":"1166866310","pubTimestamp":1636112660,"share":"https://www.laohu8.com/m/news/1166866310?lang=&edition=full","pubTime":"2021-11-05 19:44","market":"us","language":"en","title":"Pfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166866310","media":"Bloomberg","summary":"Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awa","content":"<ul>\n <li>Drug reduced Covid hospitalizations by 89% in clinical trial</li>\n <li>Pfizer shares surge 11%; Merck pill awaiting U.S. approval</li>\n</ul>\n<p>Pfizer Inc.&nbsp;said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%, a result that has the potential to upend how the disease caused by the coronavirus is treated and alter the course of the pandemic. The shares surged 11%.</p>\n<p>The drugmaker said in a statement on Friday that it was no longer taking new patients in a clinical trial of the treatment “due to the overwhelming efficacy” and planned to submit the findings to U.S. regulatory authorities for emergency authorization as soon as possible.</p>\n<p>The results mean there are now two promising candidates for treating Covid-19 patients early in the course of the disease. Last month,Merck &amp; Co.&nbsp;and partner Ridgeback Biotherapeutics LP submitted their experimental pill to regulators after a study showed it slashed the risk of getting seriously ill or dying&nbsp;by half&nbsp;in patients with mild-to-moderate Covid-19.</p>\n<p>Pfizer gained 11% in premarket U.S. trading, while Merck fell 6.6%. Some vaccine makers lost ground, with&nbsp;Moderna Inc&nbsp;.down 4.5% and Pfizer partner&nbsp;BioNTech&nbsp;SE slipping 4% in German trading.</p>\n<p>A pill that could be taken at home at the first sign of symptoms is a crucial tool for taming the Covid-19 crisis globally, so long as it’s widely available. A Pfizer spokesperson said submissions to other regulatory agencies will occur shortly after the U.S. filing.</p>\n<p>In Pfizer’s trial of 1,219 unvaccinated adults, five days of treatment with its drug dramatically reduced the rate of hospitalization when it was started within either three days or five days of symptom onset, the company said. The drug, Paxlovid, binds to an enzyme called a protease to stop the virus from replicating itself. Some drugs for HIV work in a similar way.</p>\n<p>Overall, just 0.8% of people who started treatment within three days of getting sick ended up in the hospital and no one died, while 7% of people who got a placebo in that window were later hospitalized or died. Similar results were found when the drug was started within five days of symptom onset. The result, which hasn’t been published in a medical journal, was highly statistically significant, Pfizer said.</p>\n<p><b>Acute Need</b></p>\n<p>Current treatment options for Covid aren’t ideal. Monoclonal antibodies from companies like&nbsp;Regeneron Pharmaceuticals Inc.&nbsp;and&nbsp;Eli Lilly &amp; Co.&nbsp;reduce hospitalizations, but the infusions are hard to manufacture and must be given in a medical office, adding to the strain on health systems.</p>\n<p>Other medications like&nbsp;Gilead Sciences Inc.’s remdesivir are used to treat much sicker people who are already in the hospital. Low-cost steroid dexamethasone, while very effective, is usually only given to gravely ill patients.</p>\n<p>The need for a pill is so acute that Merck has&nbsp;already agreed&nbsp;to allow generic drugmakers to apply for licenses to make its treatment for more than 100 low- and middle-income nations, before it has even been cleared in the U.S. The U.K.’s drug regulators became the first in the world&nbsp;to greenlight&nbsp;Merck’s drug Thursday after a swift review.</p>\n<p>Now Pfizer’s pill, which works by a different mechanism, appears to have produced even better results in high-risk patients. The trial was stopped early by independent monitors because the effect was so impressive.</p>\n<p>“We are really over the moon that we did see such high efficacy in this study. It has tremendous implications for patients globally,” said Annaliesa Anderson, chief scientific officer for Pfizer’s hospitals business unit, which includes its antiviral work.</p>\n<p>In addition to the current trial in high-risk patients, Pfizer is also testing the drug in standard-risk patients, a study that included some vaccinated people who had breakthrough infections.</p>\n<p>In a third large trial, Pfizer is exploring if the drug could be used as a prophylactic medicine for people who live with someone who has come down with Covid-19, meaning a person would take the drug to avoid contracting the virus.</p>\n<p><b>Old Molecule</b></p>\n<p>The pill was internally developed by Pfizer researchers in the U.S. and U.K. During the early pandemic shutdowns, the scientists agreed to come back to their labs in an urgent effort to develop anti-Covid pills, Anderson said. Company researchers “worked around the clock to design this molecule” in a highly-compressed timeframe, she said.</p>\n<p>They dusted off an old experimental antiviral drug that Pfizer had developed after the original SARS epidemic, a coronavirus cousin to Covid-19 that killed about 800 people starting in late 2002. The old drug needed to be administered intravenously. But by July of last year, the Pfizer researchers tweaked the original molecule and came up with a new compound that turned out to be highly potent against Covid-19 and other coronaviruses in the test tube -- and could be used as a pill.</p>\n<p>The Pfizer drug works to block a crucial enzyme that the Covid-19 virus needs to replicate. It is taken twice a day for five days and used in combination with a second medicine called ritonavir that helps the Pfizer compound stay in the bloodstream longer.</p>\n<p>Pfizer said it planned to offer the antiviral therapy through a tiered pricing approach during the pandemic. High and upper-middle income countries will pay more than lower income countries, it said. The drugmaker didn’t say exactly how much it would charge.</p>\n<p>A Pfizer spokesperson said the company currently expects to produce more than 180,000 packs of the drug by the end of this year, and anticipates making at least 50 million packs by the end of 2022, with 21 million produced in the first half of the year.</p>\n<p></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Develops Covid Pill That Cuts Hospitalizations and Deaths by 89%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-05 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awaiting U.S. approval\n\nPfizer Inc. said its Covid-19 pill reduced hospitalizations and deaths in high-...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-05/pfizer-to-seek-u-s-nod-for-covid-pill-after-strong-results?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166866310","content_text":"Drug reduced Covid hospitalizations by 89% in clinical trial\nPfizer shares surge 11%; Merck pill awaiting U.S. approval\n\nPfizer Inc. said its Covid-19 pill reduced hospitalizations and deaths in high-risk patients by 89%, a result that has the potential to upend how the disease caused by the coronavirus is treated and alter the course of the pandemic. The shares surged 11%.\nThe drugmaker said in a statement on Friday that it was no longer taking new patients in a clinical trial of the treatment “due to the overwhelming efficacy” and planned to submit the findings to U.S. regulatory authorities for emergency authorization as soon as possible.\nThe results mean there are now two promising candidates for treating Covid-19 patients early in the course of the disease. Last month,Merck & Co. and partner Ridgeback Biotherapeutics LP submitted their experimental pill to regulators after a study showed it slashed the risk of getting seriously ill or dying by half in patients with mild-to-moderate Covid-19.\nPfizer gained 11% in premarket U.S. trading, while Merck fell 6.6%. Some vaccine makers lost ground, with Moderna Inc .down 4.5% and Pfizer partner BioNTech SE slipping 4% in German trading.\nA pill that could be taken at home at the first sign of symptoms is a crucial tool for taming the Covid-19 crisis globally, so long as it’s widely available. A Pfizer spokesperson said submissions to other regulatory agencies will occur shortly after the U.S. filing.\nIn Pfizer’s trial of 1,219 unvaccinated adults, five days of treatment with its drug dramatically reduced the rate of hospitalization when it was started within either three days or five days of symptom onset, the company said. The drug, Paxlovid, binds to an enzyme called a protease to stop the virus from replicating itself. Some drugs for HIV work in a similar way.\nOverall, just 0.8% of people who started treatment within three days of getting sick ended up in the hospital and no one died, while 7% of people who got a placebo in that window were later hospitalized or died. Similar results were found when the drug was started within five days of symptom onset. The result, which hasn’t been published in a medical journal, was highly statistically significant, Pfizer said.\nAcute Need\nCurrent treatment options for Covid aren’t ideal. Monoclonal antibodies from companies like Regeneron Pharmaceuticals Inc. and Eli Lilly & Co. reduce hospitalizations, but the infusions are hard to manufacture and must be given in a medical office, adding to the strain on health systems.\nOther medications like Gilead Sciences Inc.’s remdesivir are used to treat much sicker people who are already in the hospital. Low-cost steroid dexamethasone, while very effective, is usually only given to gravely ill patients.\nThe need for a pill is so acute that Merck has already agreed to allow generic drugmakers to apply for licenses to make its treatment for more than 100 low- and middle-income nations, before it has even been cleared in the U.S. The U.K.’s drug regulators became the first in the world to greenlight Merck’s drug Thursday after a swift review.\nNow Pfizer’s pill, which works by a different mechanism, appears to have produced even better results in high-risk patients. The trial was stopped early by independent monitors because the effect was so impressive.\n“We are really over the moon that we did see such high efficacy in this study. It has tremendous implications for patients globally,” said Annaliesa Anderson, chief scientific officer for Pfizer’s hospitals business unit, which includes its antiviral work.\nIn addition to the current trial in high-risk patients, Pfizer is also testing the drug in standard-risk patients, a study that included some vaccinated people who had breakthrough infections.\nIn a third large trial, Pfizer is exploring if the drug could be used as a prophylactic medicine for people who live with someone who has come down with Covid-19, meaning a person would take the drug to avoid contracting the virus.\nOld Molecule\nThe pill was internally developed by Pfizer researchers in the U.S. and U.K. During the early pandemic shutdowns, the scientists agreed to come back to their labs in an urgent effort to develop anti-Covid pills, Anderson said. Company researchers “worked around the clock to design this molecule” in a highly-compressed timeframe, she said.\nThey dusted off an old experimental antiviral drug that Pfizer had developed after the original SARS epidemic, a coronavirus cousin to Covid-19 that killed about 800 people starting in late 2002. The old drug needed to be administered intravenously. But by July of last year, the Pfizer researchers tweaked the original molecule and came up with a new compound that turned out to be highly potent against Covid-19 and other coronaviruses in the test tube -- and could be used as a pill.\nThe Pfizer drug works to block a crucial enzyme that the Covid-19 virus needs to replicate. It is taken twice a day for five days and used in combination with a second medicine called ritonavir that helps the Pfizer compound stay in the bloodstream longer.\nPfizer said it planned to offer the antiviral therapy through a tiered pricing approach during the pandemic. High and upper-middle income countries will pay more than lower income countries, it said. The drugmaker didn’t say exactly how much it would charge.\nA Pfizer spokesperson said the company currently expects to produce more than 180,000 packs of the drug by the end of this year, and anticipates making at least 50 million packs by the end of 2022, with 21 million produced in the first half of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854187814,"gmtCreate":1635428404119,"gmtModify":1635428506378,"author":{"id":"3582276661346153","authorId":"3582276661346153","name":"Brugelion","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Huat ar! Buy the dip!","listText":"Huat ar! Buy the dip!","text":"Huat ar! Buy the dip!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854187814","repostId":"1153909226","repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"tweetType":1,"viewCount":570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":103118324,"gmtCreate":1619755138468,"gmtModify":1634210147039,"author":{"id":"3582276661346153","authorId":"3582276661346153","name":"Brugelion","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"这只怎么样？","listText":"这只怎么样？","text":"这只怎么样？","images":[{"img":"https://static.tigerbbs.com/59a8ba9379974aa2c5a043819af37e6a","width":"1125","height":"2197"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/103118324","isVote":1,"tweetType":1,"viewCount":525,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}